GlassScriptPhysician profile
Samir Ataya
NPI 1194766899
$2,389.90
in general payments reported to CMS, 2019-2025
18 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $216 · 2021: $71.36 · 2022: $479 · 2023: $591 · 2024: $50.08 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,057 · Travel and Lodging: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,057.23 |
| Travel and Lodging | $234.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $454.28 | 2019-2025 | Nucala, Trelegy Ellipta |
| Atricure, INC. | $298.53 | 2023 | |
| Actelion Pharmaceuticals US, INC. | $278.32 | 2019-2023 | Opsumit, Uptravi |
| Intuitive Surgical, INC. | $234.93 | 2025 | |
| Ethicon INC. | $233.09 | 2020-2023 | Monarch Platform |
| Genzyme Corporation | $176.68 | 2020-2025 | |
| Pulmonx Corporation | $125.99 | 2021-2025 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Jazz Pharmaceuticals INC. | $124.86 | 2019 | |
| Amgen INC. | $98.02 | 2019-2022 | |
| Covidien LP | $92.93 | 2020 | |
| Akcea Therapeutics, INC. | $71.88 | 2019 | |
| Verona Pharma, INC. | $48.00 | 2025 | Ohtuvayre |
| Philips North America LLC | $46.91 | 2022-2023 | |
| Medical Device Business Services, INC. | $40.40 | 2023 | Monarch |
| Sunovion Pharmaceuticals INC. | $20.42 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.61 | 2022 | |
| Insmed, INC. | $14.35 | 2025 | Arikayce |
| Inogen, INC. | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Ataya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.